GSK and CureVac to develop vaccines to tackle Covid variants
The €150m investment is to address various coronavirus strains in one jab
Full Article
GSK and CureVac to develop vaccines to tackle Covid variants
FT.com
0 shares
1 views
You might like
Related news coverage
UK backs CureVac effort to make vaccine for COVID variants
SeattlePI.com
LONDON (AP) —
The U.K. government says it will support a German biopharmaceutical company's effort to develop vaccines..
-
Government announces deal with vaccine firm to respond to Covid-19 variants
Belfast Telegraph
-
GSK, CureVac to make COVID-19 vaccines aimed at new variants
SeattlePI.com
-
GlaxoSmithKline, CureVac to make COVID-19 vaccines aimed at new variants
CBC.ca
-
Businessinsider.co.za | GSK, CureVac making 'next-generation' vaccines they say can tackle multiple Covid-19 variants at once
News24
Advertisement
More coverage
Plan to develop new vaccine that targets COVID-19 variants in one product
Sky News
Drugs giant GlaxoSmithKline and German biotech firm CureVac have struck a €150m (£130m) deal to develop next-generation COVID-19..
-
GSK and CureVac are making 'next-generation' vaccines that they say can tackle multiple COVID-19 variants at once
Business Insider
-
GlaxoSmithKline and CureVac to make Covid vaccines targeting new variants
Belfast Telegraph
-
GSK, CureVac team up to develop next generation mRNA COVID-19 vaccines
SeekingAlpha
-
GSK, CureVac to make COVID vaccines targeting new variants
SeattlePI.com